QR-Code

Nanoformulation of Talazoparib Delays Tumor Progression and Ascites Formation in a Late Stage Cancer Model

Talazoparib, a potent PARP inhibitor, induces synthetic lethality in BRCA-deficient cancers making it an attractive candidate for ovarian cancer treatment. However, its potency lends itself to side effects associated more closely with traditional chemotherapeutics than other clinically approved PARP...

Ausführliche Beschreibung

Gespeichert in:
Hauptverfasser: Paige Baldwin, Anders W. Ohman, Jamie E. Medina, Eric T. McCarthy, Daniela M. Dinulescu, Srinivas Sridhar
Format: Artigo
Sprache:Inglês
Veröffentlicht: Frontiers Media S.A. 2019-05-01
Schriftenreihe:Frontiers in Oncology
Schlagworte:
talazoparib
intraperitoneal therapy
nanoparticle
ovarian cancer
PARP inhibitor
Online-Zugang:https://www.frontiersin.org/article/10.3389/fonc.2019.00353/full
Tags: Tag hinzufügen
Keine Tags, Fügen Sie das erste Tag hinzu!

Ähnliche Einträge